Mesoblast (ASX:MSB) presents phase 3 trial results for chronic heart failure

Latest Company News - Finance News Network

English - November 15, 2021 03:17 - 1000 KB
Business News News Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Woodside (ASX:WPL) agrees to sell 49% stake in Pluto Train 2 project

Next Episode: Stocks of the Hour: Incitec Pivot, Woodside Petroleum & Mesoblast

15 Nov 2021 - Mesoblast (ASX:MSB), a global provider of allogeneic cellular medicines for inflammatory diseases, has announced that results from the randomised controlled Phase 3 trial of rexlemestrocel-L for chronic heart failure with reduced ejection fraction have been presented.